Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...

familial (congenital) partial lipodystrophy, and acquired partial lipodystrophy. Dunnigan’s syndrome is the most common type of familial partial lipodystrophies (FPLD2), holding an autosomal dominant ...

for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Each single-patient-use vial of Egrifta WR contains tesamorelin 11.6mg (equivalent to approximately 11 ...

Citation: 60 genes implicated in congenital heart disease, including some that also contribute to related disorders such as autism (2025, March 25) retrieved 17 April 2025 from https ...

A separate research letter spotlights cases of partial lipodystrophy (LD) and reminds dermatologists to consider immune checkpoint inhibition in cases of acquired LD. Both reports appeared online ...

Since 1941, when Gregg first described the triad of deafness, cataracts and cardiac disease as the classical clinical manifestations of congenital rubella syndrome (CRS), strong efforts have been ...

Arakawa died in February of hantavirus pulmonary syndrome — a rare, rodent-borne disease that can led to a range of symptoms that include flu-like illness, headaches, dizziness and severe ...

Feb. 8, 2023 — Researchers have found differences in the gut microbiomes of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to healthy controls. Findings from ...

Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy On March 25, 2025, the Company announced that ...